RxDoctor Payments Data

Melissa Rutkin

Family · Doylestown, PANPI 1255008504

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,330 of the $18,266 with a category attached, or 78.5%. Insulet Corporation accounts for 79.0% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $6,930, more than ten times the $214 reported in 2021. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,266in general payments, 2019–2025

Across 206 payments — averaging $88.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$14K
  • Medtronic$661
  • Dexcom, Inc.$467
  • Lilly USA, LLC$300
  • Novo Nordisk$291
  • Corcept Therapeutics$282
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$14,33078%
  • Food & beverage$3,92521%
  • Education$110%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,266 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide224$355,783
JardianceEmpagliflozin110$112,379
OzempicSemaglutide37$77,241
JanuviaSitagliptin Phosphate33$45,652
TrulicityDulaglutide37$44,235
Tresiba Flextouch U-100Insulin Degludec19$18,987
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$18,088
Novolog FlexpenInsulin Aspart35$13,144
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$10,530
NovologInsulin Aspart20$7,281
Nano 2nd Gen Pen NeedlePen Needle, Diabetic49$6,490
SynthroidLevothyroxine Sodium59$4,924
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,131
Metformin Hcl ErMetformin Hcl78$2,266
Levothyroxine Sodium96$1,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$300$400,018261 claims
Boehringer IngelheimJardiance$168$112,379110 claims
Novo NordiskOzempic, Novolog$291$84,52157 claims
AbbVieSynthroid$93$4,92459 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$1,57196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →